Technology Tracks Agenda

DRUG DISCOVERY CONFERENCE

18th

February, 2014

PARTNERS: Dr. Reddy's Institute of LifeSciences (ILS), CSIR-Central Drug Research Institute (CDRI)

Draft Agenda

Key Note:

9:30 A.M - 10:15 A.M

Transforming to a Patient-Based Drug Discovery Approach

Dr. AV RamaRao, Founder & Chairman, AVRA Labs, Hyderabad*

Chair: Professor Goverdhan Mehta, Univ of Hyderabad and Dr. Prabhat Arya, DRILS,

Hyderabad

Subject 1 :

10:15 A.M -11:15 A.M

Emerging Targets: Protein-

Protein Interactions (PPI) and

Signaling Pathways

Focus: Cancer, Neurological

Disorders & Metabolic Disorders

Chair: Dr. Prabhat Arya, DRILS Hyderabad and Dr. J.B Gupta, GVKBio Hyderabad

Speakers:

• Dr. Sudhir Krishna, NCBS, Bangalore

• Dr. Sorab Dalal, ACTREC, Mumbai

• Dr. Prasenjit Mitra, DRILS Hyderabad

11:15 A.M -11:30 A.M TEA BREAK

Subject 2 :

11:30 A.M -12:30 P.M

Functional Assays and High-

throughput Screens

Chair: Dr. Kiranam Chatti and Dr. Prasenjit Mitra, DRILS Hyderabad

Speakers:

• Dr. Monalisa Chatterji, Astra Zeneca, Bangalore

• Dr. Kiranam Chatti, DRILS Hyderabad

• Dr. Prasenjit Mitra, DRILS Hyderabad

Subject 3 :

12:30 P.M - 01:30 P.M

3D Cell Biology for Screening

Chair: Dr. Gael Stephant, Paris* or Dr. Mike Renard*

• 3D Microtissues and Cell based Assays

• Toxicology Screens

Speakers:

• Dr. Wolfgang Moritz*/ Dr. Jens Kelm Insphero, Switzerland*

• Dr. Keith Murphy, Organovo, US*

01:30 P.M -02: 45 P.M LUNCH BREAK

02:45 P.M -03:15 P.M Innovation Talks: A Novel Versatile Human Cell Based in Vitro High Throughput

Genotoxicity Screen

Dr. Sunilkumar Sukumaran, Anthem Bioscience Bangalore

Subject 4 :

03:15 P.M -04:15 P.M

Chemical vs Biological Space

Chair: Dr. Prabhat Arya and Dr. Amit Mandal, DRILS Hyderabad

Speakers:

• Dr. G. Narahari Shastry, IICT Hyderabad

• Dr. Prabhat Arya, DRILS Hyderabad

Round Table :

4:15 P.M - 05-00 P.M

Problem Solving Agenda

(Round Table)

Strength of small molecules pipeline – Drivers & Barriers

Moderator - Dr. Prabhat Arya, DRILS Hyderabad and Mr. Arvindh Shanmugam,

Independent Consultant, Chennai

• Enzyme vs protein-protein interaction-based targets

• Functional assays

• Chemical vs biological space

• Upcoming challenges and opportunities for the CROs

• Basic science discovery to translational path

• Fostering academia-industry relationship to develop new research models

Panel:

Dr. JB Gupta - GVKBIO, Dr. Nishi - CEO Daiichi, Dr. CSN Murthy, Aurigene,Dr. Reddy's,

Jubilant, Dr. Raman Bakshi -Syngene, Dr. Satish Jindal - BMS, ChemBioTech, Dr. Renu

Swarup, DBT - BIRAC

BIO-THERAPEUTICS CONFERENCE

18th

February, 2014

Organizers:

Federation of Asian Biotech Association, Government of Andhra Pradesh, Pharmexcil, Ministry of

Commerce & Industry, Government of India

Partners:

Insight Bioventures India Private Limited, ACTREC, United States Pharmacopeia

Draft Program Agenda

9:30 - 10:15 Hrs

Keynote

Bio-Therapeutics - Unfolding Next Generation Biologics

Prevention of infections linked to human cancers

Prof. Dr. Harald zur Hausen (Nobel Laureate), University of Heidelberg, Germany

10:15 -11:15 Hrs

(Subject 1)

Next Generation

Biologics

mRNA CAR Engineered T-cell Immunotherapies

Dr. Madhusudan Peshwa, MaxCyte, Inc. Washington

Therapeutic Proteins for Diabetic foot ulcer (DFU)

Dr. Theresa O'Keefe, Mend Therapeutics Inc., Boston

Multispecifics: DVD-iG Technology

Dr. Subramanya Hegde *, AbbVie Inc., Boston

11:15 -11:30 Hrs Tea / Coffee Break

11:30 A.M -12:30 P.M

(Subject 2)

Cancer Bio-

Therapeutics

Chair: Dr. Shubhada Chiplunkar* , Director, ACTREC

Development & Commercialization of Enhanced Potency Dendritic Cell Vaccines for Cancer


Lethal Seeds in the Womb: Endometrial Cancer Stem Cells Express Metastasis Tumor Antigen

Dr. Asha Nair, Rajiv Gandhi Centre for Biotechnology, Kerala

12:30-13:45 Hrs Lunch Break

13:45-15:30 Hrs

(Session 3)

Coordinated by United

States Pharmacopeia

Critical Quality Attributes of Biotherapeutic Proteins and Biosimilars

Dr. Sridevi Khambhampaty, Sr. Director, Dr. Reddy’s lab

Critical Quality Attributes of Vaccines

Dr. Mahesh Bhalgat, COO, Shantha Biotech

Quality Attributes of Biologic Medicines and USP Standards

Dr. Ranjan Chakrabarti, Vice President, United States Pharmacopeia-India

15:30-16:15 Hrs

(Session 4)

Bio-Engineering & Bio-

processing Innovation

Dr. Ralf Klein

ViruSure GmbH

Alternative expression system that will reduce the cost of production of therapeutic proteins

Dr. Jagmohan Singh, IMTECH

Rapid scalable. cGMP-compliant 'plug and play' platform for Manufacture of Multigram

Quantities of Recombinant Proteins, Antibodies & Vaccines


16:15- 17.00Hrs Problem Solving Framework - Next Generation Biologics in India – Drivers & Resistors

* indicates invited confirmation awaited

BIO-ENERGY CONFERENCE 18

th February, 2014

PARTNERS: Ministry of New and Renewable Energy (MNRE), The Energy and Resources

Institute (TERI), & CSIR-Indian Institute of Chemical Technology (CSIR-IICT)

Draft Agenda

09:00-09:30 A.M INAUGURATION by Dr Satish Balram Agnihotri, Secretary to Government of India,

Ministry of New and Renewable Energy*

9:30 - 10:15 A.M

Keynote

Sustainability Assessment to Promote Holistic Bio-Energy Production – Feedstock,

Technology & Regulations

Dr. Jean-Marc Jossart *, Secretary General, AEBIOM-European Biomass Association,

Belgium (or)

Dr. David Hurlbut *, National Renewable Energy Laboratory, USA

10:15 - 11:15 A.M

(Session 1)

Bio-Feedstock

Supplies–

comparative analysis

of various feedstock

sources

Chair:

Mr. Amit Kumar *, Director, Energy-Environment Technology Development Division,

TERI, New Delhi

- Energy Plants – Alternatives

-Agri-residue biomass collection, logistics

-Algae

-Biomass

-Next Generation Alternatives

Proposed Speakers

• Dr. Murali Sastry, Director, DSM India Innovation Centre

• Dr Pankaj Patel - Director, Abellon CleanEnergy Ltd

• Dr.Ashwani Kumar, BioEnergia

• Dr. Shibu Jose, UM, Columbia, MO, USA

• Dr. D K Tuli , Executive Director & Centre Coordinator, DBT-IOC Advanced Bio-

Energy Research Centre, Indian Oil Corporation Ltd, Faridabad

• Dr Ahmed Kamal, IICT, Hyderabad

• Dr P Srinivasa Rao, Senior Scientist, ICRISAT, Patancheru, India

• Dr. Priyangashu Sarma , Fellow, TERI, New Delhi

11:15 -11:30 A.M Tea / Coffee Break

11:30-12:30 P.M

(Session 2)

BEMA:

Biotechnology,

Engineering, Micro-

Biology &

Agriculture

Chair – Mr. A P Dhussa *, Scientist-G/Advisor, Ministry for New and Renewable

Energy, Government of India, New Delhi /Dr Ahmed Kamal *, Outstanding Scientist,

CSIR-IICT, Hyderabad and Director, NIPER, Hyderabad

-Bio-Refinery Technologies

-Genetic Improvement of Energy Crops

-Strains and Enzyme Technology (Biomass Digestion)

-Mass Production of Energy Crops

Proposed Speakers

• Prof. K T Shanmugam, University of Florida, USA

• Prof. Hornung, Director - European Bioenergy Research Institute

• Dr. Arvind Lali, Centre Coordinator, DBT-ICT Center for Energy Biosciences,

Institute of Chemical Technology, Mumbai

• Mr. Laxmi Narasimhan, General Manager, Centre for Novel Catalytic

Materials, Shell Technology Centre, Shell India Marketing, Bangalore

• Dr S V Ramakrishna (earlier worked with Reliance and Praj in their biofuel

programs as research director)

• Mr. Subramani Ramachandrappa - CMD Richcore India

• DrAlok Adholeya, Director, Biotechnology and Management of Bio-resources

Division, TERI, New Delhi

• Dr. Ashok Pandey, Head, Centre for Biofuels, NIIST, Thiruvananthapuram

• (If a speaker needed on liquid fuels) Dr. Piyali Das, Fellow, TERI, New Delhi

12:30-1:30 P.M

(Session 3)

Industrial Bio-energy

& Commercial

Deployment

Chair - Mr. Pramod Chaudhari *, Executive Chairman, Praj Industries Limited and

Chairman, Praj Group, Pune, India

-Torreication Technology

-CHP Deployment & scalability

-DFC for Anaerobic Digestion

-Industrial bio-energy economics

Proposed Speakers

• Dr. Ludo Diels, Senior Scientist and Head of the Environmental and Process

Technology Centre, VITO, Belgium

• Dr Syed Isa Syed Alwi, CEO, AlgaeTech International, Malaysia

• Dr. R R Sonde, Executive Vice President, Research, Technology & Innovation,

Thermax India

• Mr. Sunil Dhingra, Senior Fellow, TERI, New Delhi

• Dr. Balu Sarma

1:30 - 2:45 P.M Lunch Break

2:45 - 3:15 P.M

Innovation Talk

K.Sudhakar, NIT-Bhopal & Five more speakers

3:15 - 4:15 P.M

(Session 4)

Regulations – New &

Renewable Energy

as a legislation &

Directive

Chair - Shri Alok Srivastava *, Joint Secretary, Ministry for New and Renewable

Energy, Government of India, New Delhi

Proposed Speakers

• Dr. Chris Mottershead, The Carbon Trust, London, UK / Richard Adams, NREL /

David Hurlburt NREL Policy Analysis group

• Dr. Renu Swarup, Adviser, Department of Biotechnology, Ministry of Science

& Technology, Government of India and Managing Director, Biotechnology

Industry Research Assistance Council

• Mr. Anil Kumar Jain, Adviser (Energy), Planning Commission, Government of

India

• Dr K V Raghavan, Vice President, FABA, Ex Director CSIR-IICT, Hyderabad

• Mr. K Krishan, Chairman CII Task force on Bioenergy and Chairman, MPPL

Renewable Energy Pvt. Ltd.

• Prof. Janaki/Dr Pankaj USA

4:15 - 5:30 P.M Problem Solving Agenda

Creating the Bio-Energy Economy of India – Drivers & resistors

Coordinated by PHARMEXCIL

For registrations Contact – [email protected] | Telephone: +91-40-6644-6477/6577

GENOMIC-PERSONALIZED MEDICINE CONFERENCE Hyderabad International Convention Center, Hyderabad

Chairman: Prof. Donald W. Weaver, Surgeon-in-Chief, Detroit Medical Center (DMC), Chief of

Surgery at Harper University Hospital, Chairman of Department of Surgery, Wayne State University

School of Medicine, USA

Conveners:

Dr. Ramesh B. Batchu, Associate Professor, Dept Surgery, School of Medicine Director,

Division of Surgical Oncology & Developmental Therapeutics, Dept Immunology and

Microbiology, John D Dingell VAMC, Wayne State University

Dr Cirino Botta, MD, Medical Oncology Unit, Fondazione Tommaso Campanella & Magna

Graecia University of Catanzaro, Italy

Draft Program Agenda

09:30-10:00 Hrs “Personalized Medicine: Tailor-made for individual patient”

Personalized medicine is the ability to determine an individual's unique molecular

characteristics to propose customization of medical care more finely suited to a patient.

The availability of genetic information due to successful human genome project has

played a major role in the ability to predict an individual's susceptibility to diseases.

This will allow protocols designed specifically based on the patient’s response to

treatment.

Prof. Donald W. Weaver MD, FACS, Surgeon-in-Chief, Detroit Medical Center (DMC), Chief

of Surgery at Harper University Hospital, Chairman of Department of Surgery, Wayne State

University School of Medicine, USA

10:00-10:20 Hrs Adeno-associated Viral vectors in Genomic Medicine and cell based treatment

Gene therapy with traditional viral vectors is limited by a variety of practical and

theoretical concerns, such as the immunogenicity of viral capsid proteins and insertional

mutagenesis. Adeno-associated virus (AAV) is a small, 4.7kb, non-enveloped DNA virus

initially identified as a contaminant in adenoviral preparations. Bioengineered

recombinant AAV (rAAV) vectors are preferred for gene therapy due to their lack of

pathogenicity, wide range of infectivity, and ability to establish long-term transgene

expression in non-dividing cells. Furthermore, with only a modest frequency of

integration into the host genome, they avoid insertional mutagenesis. Finally, rAAV

vectors per se induce only weak innate immune responses when compared to other



viral-based vectors. rAAV vectors have yielded promising results in an increasing

number of somatic gene therapy clinical trials without any significant adverse events.

However, despite the well-established safety of rAAV vectors for in vivo gene transfer,

several challenges remain, such as achieving high levels of transduction in targeted

organs and inhibiting cytoplasmic degradation of a high percentage of virions during

intracellular trafficking to the nucleus. Indeed, rAAV capsids are phosphorylated,

marking them for ubiquitination followed by proteasome-mediated degradation in the

cytosol. Thus, higher doses of vectors are needed to obtain therapeutically relevant

concentrations in patients. The development of next generation of capsid-modified rAAV

vectors, which bypass ubiquitination and proteasome degradation, leading to high

efficiency gene transfer and transgene expression at reduced doses, and their utility in

genomic medicine will be discussed.

Dr. Arun Srivastava, George H. Kitzman Professor of Genetics and Chief of Division of Cellular

& Molecular Therapy in the Departments of Pediatrics, and Molecular Genetics & Microbiology,

and Powell Gene Therapy Center, University of Florida, USA

10:20-10:40 Hrs Urological cancers, biomarkers and cancer pathway inhibitors

Immune status of every tumor and the way its cells respond to the local environment is

different, based on the genetic profile of patients. The tumor grade may be the same from

patient to patient, but the pathways for escape and resistance may be different.

Genomics and proteomics-guided treatment of individual patients is the direction we

should be taking to manage malignancies. This holds true not only when it comes to

predicting progression and aggression of tumors where we need to be pairing

therapeutics based on the genetic/protein marker. Each patient with urological cancer

has a distinct histology, a different clinical course and responds differently to therapy.

For example genomic studies in identifying the genes for kidney cancer, such as

fumarate hydratase, and succinate dehydrogenase have significantly altered the ways in

which patients with kidney cancer are managed.

Dr. Jose Pontes, MD, Urologist, Detroit, MI, USA

10:40-11:00 Hrs Tea / Coffee Break

11:00-11:20 Hrs Gene-based treatment for Head and Neck Cancers

Although some head and neck cancers are diagnosed early in the disease progression,

silent lesions unfortunately are not diagnosed until regional spread has already

occurred. The stage at the time of diagnosis for cancer of larynx with early symptoms of

hoarseness is much lower than that of a base of tongue cancer, which often lacks

symptoms, until later in the disease course. Infection with human papilloma virus

(HPV) increases one’s odds of developing squamous cell carcinoma of the oral pharynx.

As smoking has decreased, the incidence of HPV associated cancers has increased.

Understanding the genetic basis of this specific subtype of cancer could allow

therapeutic targeting of affected pathways for a stratified medicine approach. Gene

profile analysis of various head and neck cancers revealed altered pathways in p53 and



Rb mutation and copy number alteration of PI3 kinase pathway. Additional observations

of alternative pathways have been made in cancers of the thyroid. Whole genome

sequencing and identification of gene expression patterns will be required to gain a

complete understanding of the genetic basis of head and neck cancers to provide the

foundation for the development of effective forms of therapy.

Prof. John R Jacobs MD FACS, Departments Otolaryngology Head and Neck Surgery, Wayne

State University, Karmanos Cancer Center, USA

11:20-11:40 Hrs Genetic Immunotherapy with Dendritic Cells for Individualized Cancer Vaccine

Dendritic cells (DC) are highly specialized antigen-presenting immune cells and key

regulators of the immune responses that orchestrate innate and adoptive immunities

throughout the body. They are responsible for identifying tumor markers to activate

cytotoxic T lymphocytes, which then multiply and attack only the diseased cells, but not

normal healthy cells. This is a potent form of immunotherapy to harness the body's own

immune system to fight cancer. Use of non-pathogenic recombinant adeno-associated

viral (rAAV) vectors can achieve high levels of intracellular tumor specific gene

expression in DCs with much lower doses of vector and generation of robust cellular

anti-tumor immune responses. Gene-vector based immunotherapy with DCs would

pave the way for development of a therapeutic vaccine strategy to achieve durable tumor

regression specific to individual patients.

Prof. Selvarangan Ponnazhagan, Endowed Professor in Experimental Cancer Therapeutics,

The University of Alabama at Birmingham, USA

11:40-12:00 Hrs Personalized Therapeutic Vaccines

Therapeutic vaccinology will allow the development of personalized vaccines based on

our increasing understanding of immune response phenotype: genotype information.

Rapid advances in developing such data are already occurring for numerous diseases

and newly available data suggest that some vaccine-related adverse events may also be

preventable based on genetic prediction.

Dr. Bala Krishna Kolli, Rosalinda Franklin University of Medicine and Science, North

Chicago, IL, USA

12:00-12:20 Hrs Role of Bioinformatics in Personalized Medicine

In the genomic era: doctors and patients will have access to genetic data to customize

medical treatment. In recent past, molecular science has made many advances to benefit

medicine, including the Human Genome project, International HapMap project and

genome wide association studies (GWASs) (International HapMap Consortium, 2005).

Single nucleotide polymorphisms (SNPs) are now recognized as the main cause of

human genetic variability and are already a valuable resource for mapping complex

genetic traits. Thousands of DNA variants have been identified that are associated with

diseases and traits. By combining these genetic associations with phenotypes and drug

response, personalized medicine will tailor treatments to the patients’ specific genotype.



Anticancer drugs which target to specific cancers, and use of pharmacogenetic dosing

algorithm, reduction of incidence of adverse events by screening for susceptible

genotypes for certain drugs underscore the importance of bioinformatics approach in

personalized medicine.

Dr. Ravindra B Potti, Associate Professor, Department of Biotechnology, Sreenidhi Institute of

Science and Technology, Hyderabad

12:20-13:00 Hrs Interaction and Close

Bio-IT Conference 19

th February, 2014

Draft Agenda

Key Note:

9:30 A.M - 10:15 A.M

BioPharma Big Data Paradigm

Dr. Nitish Chawla, University of Notre Dame, Indiana, US

(2013 IBM Big Data Innovation Award winner)

Subject 1 :

10:15 A.M - 11:15 A.M

Computational

Therapeutics

Session Chair: Dr. Vellarkad N. Viswanadhan, Jubilant Biosys

Computational Drug Design

Dr. Frank Hollinger - Sphaera Pharma

Computation Guided Vaccine Design Integrative approach for designing of Epitope-based

vaccine using in silico platform OSDD Linux

Dr. GPS. Raghava – IMTECH

Blast Off! Exploring the universe of biochemical reactions

Dr. Rahman Syed Asad., EMBL – EBI, Cambridge, UK

11:15 A.M - 11:30 A.M TEA BREAK

Subject 2 :

11:30 A.M - 12:30 P.M

Cross Platform Omics for

Translation Research

BioMarker Discovery for Translational Prediction

Dr. Pramila Tata - Strand Life Sciences

Integrative Omics – Interactome Models

Mr. Jignesh Bhate – Molecular Connections

Translational Informatics

Dr. Ajay Shah, City of Hope, CA, US*

Systems Pharmacology

Dr. Rajgopal Srinivasan – TCS Innovation Labs

Subject 3 :

12:30 P.M - 1:30 P.M

Data capture & Analytics

Chair: Mr. Raghu Rangaswamy, Schroedinger

Preserve, Protect & Collaborate via Scilligence Informatics (ELN)

Mr. Rajiv Hotchandani- Scilligence

Data Pipeline Management: Pipeline Pilot

Proposed: Accelrys

Registration Systems (Chemical & Biological)

Mr. Ivan Solt – Chemaxon, Hungary*

Process Analytics: Reaction Data Kit Demonstration

Mr. Ramakrishna Bodi, KNIME*

1: 30 P.M - 02:30 P.M Lunch Break

02:30 P.M - 03:00 P.M

Innovation Talks

Subject 4 :

03:00 P.M - 04:00 P.M

Big Omics Data

Management, Challenges

Drug R & D Knowledge Mining Made Simple: A Scilligence Perspective

Dr. Jinbo Lee, CSO, Scilligence

Cloud Computing and Innovations for Optimizing Life Sciences Research

Ms. Krittika Sasmal , iOMICS, InterpretOmics

SaaS, IaaS and PaaS options for IT Investment Optimization

Proposed Speaker from Accenture, IBM

Round Table :

4:00 P.M - 04-30 P.M

Problem Solving Agenda

Problem Solving Agenda:

Bio-IT – Leveraging IT Investments in Bio-Pharma R&D (Drivers & Barriers)

REGENERATIVE MEDICINE CONFERENCE

19th

February, 2014

PARTNERS: Integrative Regenerative Medicine (IGEN) Center, Society for Tissue Engineering &

Regenerative Medicine (STERMI), Sankara Netralaya Translational Research Institute (SNTRI)

Draft Agenda

Key Note:

9:30 A.M - 10:15 A.M

Chair: Prof. Zee Upton, Queensland University of Technology

Guest: Dr. Michael West, Chairman BioTime Inc.

Doing more with less: Frugal innovation in Regenerative Medicine –

Dr. Mahendra Rao, Director The NIH Center for Regenerative Medicine, USA

Subject 1 :

10:15 A.M -11:15 A.M

Comparative

Therapeutic Potential

of various Stem Cell

Chair: Dr. Utpal Banerjee, UCLA*

Embryonic Source (Pure Stem)

Dr. Jeffey Janus, ESI Bio/BioTime (or) Dr. James Kehler, BioTime

Induced Pluripotent Stem Cells –

Dr. Ullas Mony*

Dr. Alok Srivastava, CMC*

Dr. James Byrne, UCLA*

Adult stem cells, their potential and their comparison with ESCs

Dr. Chandra Viswanath - Reliance Life Sciences

Therapeutic potential of Hematopoietic and Mesenchymal stem cells derived from cord tissues

Dr. Lalitha Limaye, NCCS, Pune

11: 15 A.M–11: 30 P.M TEA BREAK

Subject 2 :

11:30 A.M -12:30 P.M

Characterization,

Reprogramming,

Differentiation &

Analysis of Stem Cells

Chair: Dr. Vincent Zurawski, Hepregen Corporation*

Biomarker discovery for stem cells using omics,

Dr. Vivek Tanavde, Bioinformatics Institute, Singapore

Cell Reprogramming

Dr. P Chandrashekar, inStem*

Epigenetic analysis & Characterization

Dr. Rachna Goyal, Lonza

Engineering Adult Stem Cells to Enhance their Potency & Therapeutic Efficacy


Subject 3 :

12:30 P.M -01:30 P.M

3D Biology & Tissue

Engineering

Chair: Dr. Seeram Ramakrishna - NUS, Center for Nanofibres & Nanotechnology

Biomimetic Building Blocks

Dr. Jaywant Phophase, IGEN, Linkoping University, Sweden

3D Biology for RM

Dr. Gael Stephant, Paris*

Tissue Engineering & Bio-printing Technology

Dr. Sourabh Ghosh, IIT Delhi

Bio-printing Technology

Dr. Keith Murphy, Organovo, San Diego*

Dr. Michael Renard, Organovo, San Diego*

Brain Organoids

Dr. Juergen Knoblich, IMBA - Institute of Molecular Biotechnology, Austria*

(Or)

Liver Organoids

Dr. Nuria Montserrat, Centre of Regenerative Medicine in Barcelona*

1:30 P.M -2:30 P.M LUNCH BREAK

02:30 P.M -03:00 P.M Innovation Talks

Subject 4 :

3:00 P.M -04:00 P.M

Specialty Trends

Chair: Prof. Nisha R Agrawal, Banaras Hindu University, Varanasi

Bone & Cartilage

Dr. Sudhir Kumar Reddy, ISCO Cell Therapeutics

Neural

Dr. NK Venkatarama*/Dr. Basha Paspala

Cardiac

Dr. Arjun Deb, MD, Board of Stem Cells, UCLA, USA*

Ophthalmology

Dr. Krishna Kumar, Vision Research Foundation, Sankara Nethralaya

Dr. Doris Taylor, Centre for Cardiovascular, University of Minnesota*

Round Table :

4:00 P.M – 04:30 P.M

Problem Solving Agenda : Stem Cell & Regenerative medicine - Drivers & Barriers

Medical Electronics and Devices Conference 19th February, 2014

DRAFT AGENDA

09:30 – 10:15 Hrs INAUGURAL CEREMONY

Chief Guest:

Minister of State, Department of Commerce, Government of India*

Guests of Honour:

• Shri J. Satyanarayana, IAS, Secretary to the Government of India, Department of Electronics and Information Technology (DEITY), Ministry of Communications & Information Technology (Government of India)*

• Shri. Pradeep Chandra IAS, Principal Secretary to the Government of Andhra Pradesh, Department of Industries and Commerce

Keynote Address: India’s vision and Strategy on MedTech Dr. Ajay Kumar IAS, Joint Secretary to the Government of India, Dept. of Electronics and Information Technology*

10:15 – 11:15 Hrs Medical Technologies – India for India

“The Indian Medical Device & Equipment market is currently valued at $ 4.4 billion and is expected to grow to around $ 5.8 billion by 2014 and $ 7.8 billion by 2016, growing at a CAGR of 15.5 per cent", according to an industry report. As the sector gains traction continually over the years, there is a perpetual demand for high quality products. There were around 356 registered manufacturing units producing medical devices of the value of outputs of `312 crores in 2009‐10. There are only few units manufacturing medical devices compared to the growing manufacturing sector in India. The session will focus on the gap between the supply and demand such that the Indian production can cater to the local demand than relying on exports

Lead Speaker:

Mr. M.R. Srinivas Prasad, CEO , Philips Innovation Campus

Panelists:

• Mr. M.R. Srinivas Prasad, CEO , Philips Innovation Campus

• Mr. Suresh Sharma, Chairman & Managing Director, Allengers Medical Systems Limited*

• Mr. Ajit G Nambiar, Chairman & Managing Director, BPL Healthcare*

• Dr. K. K. Kalra, CEO, National Accreditation Board for Hospitals & Healthcare Providers (NABH)

• Shri. Arun Sachdeva, Senior Director (Scientist‐G), Department of Electronics and Information Technology (DEITY), Government of India

Moderator: Mr. Mahadevan Narayanamoni, Partner, Corporate Finance and Life Sciences, Grant Thornton

11:15 – 11:30 Hrs TEA / COFFEE BREAK

11:30 – 11:45 Hrs Opportunities in Gangwon (South Korea)

11:45 – 12:30 Hrs MedTech – Ensuring Quality and Patient Safety

Growing demand of efficacious and quality treatments has accelerated the growth of MedTech Sector. As with every new emerging technology, there are potential risks with such new technologies, and testing & calibration holds the key. Availability of skilled manpower and huge talent pool of engineers in India makes it a strategic destination for testing and calibration forglobal companies. The session shall focus on ways and means to enhance patient safety and quality of medical technologies through strengthening the testing and calibration laboratories in

India and the potential role that Industry and Government (both state and central) have to play

Chairman: Mr. S. Kishore Kumar, Scientist‐F & Head, Medical and Hospital Planning, Bureau of Indian Standards, Government of India

Panelists:

• Mr. Sundeep Rao, Vice President, Philips Electronics India Limited*

• Mr. Suresh Sugavanam. Vice President & Managing Director at Underwriters Laboratories

• Mr. G. Kalyan Varma, Country Head, Products Business Stream, TUV Rheinland India

• Dr. G.S.K. Velu, Managing Director, Trivitron Laboratories*

• Dr. Chander Shekhar, Scientist ‐ 'F', Indian Council of Medical Research (ICMR)

• Dr. Devasis Guha, Head, R & D, HLL Lifecare Limited*

Moderator: Dr. Girdhar J Gyani, Director General, Association of Healthcare Providers (India)*

12:30 – 13:30 Hrs India as Manufacturing Hub

The influx of Medical Electronics technology has reinforced the existing Healthcare infrastructure in various ways right from digitizing medical test, diagnostic and therapeutic procedures to enhancing the reach of Healthcare through telemedicine and Health IT. A number of international companies have set up manufacturing facilities in India and given the tremendous benefits of cost economics, India promises to be the manufacturing hub for MedTech

Lead Speaker:

Mr. Vikram Damodaran, Chief Technical Officer, GE Healthcare India*

Panelists:

• Mr. Kaustubh Patil, Program Manager, Medtronic India Development Center*

• Mr. Subramanian, Director, SCS systems*

• Mr. Vinayak Khandeparker, Quality Head, Siemens India*

• Dr. Shahid Jameel, Senior Scientist and Group Leader, ICGEB*

Moderator: Mr. Vijay Simha, CEO, One Breadth Inc.

13:30 – 14:30 Hrs LUNCH BREAK

14:30-15:30 Hrs Creating a conducive Policy Environment in India: Way Forward

While the sector faces challenges in particularly in terms of low penetration, high capital requirement, complex rules & guidelines, acceptability, awareness, etc., the future looks extremely promising with the increased public spending & private investment in healthcare, health insurance schemes, public private partnership (ppp) route to innovation, etc. This panel is structured to be a discussion with the key policy makers to understand from them on enabling a fostering environment for the growth of the sector

Panelists:

• Dr. Ajay Kumar IAS, Joint Secretary to Government of India, Department of Electronics and Information Technology (DEITY)*

• Mr. S. Kishore Kumar, Scientist‐F & Head, Medical and Hospital Planning, Bureau of Indian Standards, Government of India

• Shri S. B. S. Reddy, ITS, Regional Jt. DGFT (Directorate General of Foreign Trade)

• Mrs. Anuradha Gupta, Joint Secretary, Ministry of Health & Family Welfare (PNDT)*

• Dr. Sadhana Srivastava, Scientist E, IPR Unit, Department of Health Research, Indian Council of Medical Research (ICMR)

• Dr. Rashid Hasan, Director, Ministry of Environment & Forests (MoEF)*

Moderator: Mr. Karan Singh, Partner, Bain & Company*

15:30-15:45 Hrs China Medical City-Opportunities in China

15:45 -16:30 Hrs Concluding Remarks by the coordinators and Event Close

Mr. Sudhakar Mairpadi, Head Regulatory Affairs, Philips Mr. Vibhav Garg, Head, Health Economics & Government Affairs, Boston Scientific

Technology Tracks Agenda

Documents

Transcript of Technology Tracks Agenda